Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EPS (Weighted Average and Diluted) (2021 - 2025)

Janux Therapeutics (JANX) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.51 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 45.71% to -$0.51 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.83 through Dec 2025, down 44.09% year-over-year, with the annual reading at -$1.83 for FY2025, 42.97% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.51 at Janux Therapeutics, down from -$0.39 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.11 in Q2 2024, with the low at -$0.62 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.37, with a median of -$0.39 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 73.81% in 2024, then tumbled 400.0% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.29 in 2021, then crashed by 34.48% to -$0.39 in 2022, then soared by 38.46% to -$0.24 in 2023, then crashed by 45.83% to -$0.35 in 2024, then plummeted by 45.71% to -$0.51 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.51, -$0.39, and -$0.55 for Q4 2025, Q3 2025, and Q2 2025 respectively.